accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed over 500 companies over five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe from its headquarters in Paris with a portion of investments made in the rest of the world.

View More

Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study                       Paris, 6 July 2020 – 7.00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX...

- Dr Moses is internationally recognized as a leading CEO and Chairman of life science companies - Dr Moses led the rapid growth of Ablynx from a platform technology to a fully integrated biopharmaceutical company prior its acquisition by Sanofi - Appointment ...

PARIS, FRANCE / ACCESSWIRE / July 2, 2020 -- MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from the Sofinnova Partners MD Start III Fund, as well as an addi...

Investments in innovative medical devices follow the fund’s initial closing in May 2019   PARIS, France – July 2, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second inve...

DJ Redx Pharma plc Proposed financing of $30m and notice of GM   TIDMREDX RNS Number : 4498R Redx Pharma plc 30 June 2020 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MA...

Martin T. Rothman

Martin T. Rothman

Venture Partner

MEET OUR TEAM